CA2533715A1 - Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction - Google Patents

Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction Download PDF

Info

Publication number
CA2533715A1
CA2533715A1 CA002533715A CA2533715A CA2533715A1 CA 2533715 A1 CA2533715 A1 CA 2533715A1 CA 002533715 A CA002533715 A CA 002533715A CA 2533715 A CA2533715 A CA 2533715A CA 2533715 A1 CA2533715 A1 CA 2533715A1
Authority
CA
Canada
Prior art keywords
compound
disorder
patient
effective amount
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002533715A
Other languages
English (en)
French (fr)
Inventor
Anima Ghosal
Wei Tong
Swapan K. Chowdhury
Shmuel Zbaida
Mark A. Wirth
Kevin B. Alton
James E. Patrick
Craig D. Boyle
Andrew Stamford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2533715A1 publication Critical patent/CA2533715A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002533715A 2003-07-31 2004-07-29 Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction Abandoned CA2533715A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49221803P 2003-07-31 2003-07-31
US60/492,218 2003-07-31
PCT/US2004/024525 WO2005012303A1 (en) 2003-07-31 2004-07-29 Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
CA2533715A1 true CA2533715A1 (en) 2005-02-10

Family

ID=34115611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002533715A Abandoned CA2533715A1 (en) 2003-07-31 2004-07-29 Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

Country Status (10)

Country Link
US (1) US7312223B2 (enExample)
EP (1) EP1648895B1 (enExample)
JP (1) JP2007500714A (enExample)
CN (1) CN1860119A (enExample)
AT (1) ATE363483T1 (enExample)
CA (1) CA2533715A1 (enExample)
DE (1) DE602004006756T2 (enExample)
ES (1) ES2284056T3 (enExample)
MX (1) MXPA06001195A (enExample)
WO (1) WO2005012303A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60307628T2 (de) * 2002-05-31 2007-08-09 Schering Corporation Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
WO2006023603A2 (en) * 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
KR20090087795A (ko) * 2008-02-13 2009-08-18 한양대학교 산학협력단 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US20100261737A1 (en) * 2009-04-10 2010-10-14 Medtronic Vascular, Inc. Method of Treating Erectile Dysfunction
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
CN106770618A (zh) * 2015-11-20 2017-05-31 中国康复研究中心 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL98559A0 (en) 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5409934A (en) * 1990-12-21 1995-04-25 Smith; David G. Xanthine derivatives
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
HUT72640A (en) 1993-02-26 1996-05-28 Schering Corp 2-benzyl-polycyclic guanine derivatives, pharmaceutical compositions containing them and process for preparing them
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PE20040538A1 (es) 2002-05-31 2004-08-30 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
DE60307628T2 (de) 2002-05-31 2007-08-09 Schering Corporation Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen

Also Published As

Publication number Publication date
DE602004006756T2 (de) 2008-01-24
JP2007500714A (ja) 2007-01-18
EP1648895B1 (en) 2007-05-30
EP1648895A1 (en) 2006-04-26
WO2005012303A1 (en) 2005-02-10
HK1082739A1 (en) 2006-06-16
DE602004006756D1 (de) 2007-07-12
US20050026939A1 (en) 2005-02-03
CN1860119A (zh) 2006-11-08
ATE363483T1 (de) 2007-06-15
MXPA06001195A (es) 2006-04-11
ES2284056T3 (es) 2007-11-01
US7312223B2 (en) 2007-12-25

Similar Documents

Publication Publication Date Title
CA2716788C (en) Deuterium-substituted xanthine derivatives
JP2613355B2 (ja) パーキンソン氏病治療剤
CA2771123C (en) Substituted xanthine derivatives
AU777571B2 (en) 8-phenyl-6,9-dihydro-(1,2,4)triazolo(3,4-i)purin-5-one derivatives
WO2013105063A1 (en) Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
AU2010289551A1 (en) Substituted xanthine derivatives
KR102834472B1 (ko) 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
BG61728B1 (bg) 2,9-дизаместени пурин-6-они
CA2658404A1 (en) Selective antagonists of a2a adenosine receptors
EP1648895B1 (en) Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
EP3068391B1 (en) Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US8349848B2 (en) Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
US4985433A (en) 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
JP2021529819A (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
DE602004012146T2 (de) Pyrazolopyrimidine
CN113943288A (zh) 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN114901649B (zh) Ssao抑制剂及其用途
EP3565817A1 (en) SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (nSMase2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN115768775B (zh) Idh突变体抑制剂及其用途
HK1082739B (en) Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
EP1307458B1 (en) Pyrrolotriazolopyrimidinone derivatives
CN117222648A (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
CN117412971A (zh) 含吡嗪结构的吡咯并嘧啶衍生物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued